Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of Palivizumab for Prevention of Severe RSV in High-risk Young Children
jRCT2080224862Phase 2Completed
- Sponsor
- Mori Masaaki, MD, Ph.D.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palivizumab in respiratory syncytial virus disease (RSV), sponsored by Mori Masaaki, MD, Ph.D. Primary endpoints: Safety of palivizumab prophylaxis and Prevention of serious respiratory symptoms and RSV-related hospitalization. Started Sep 2019; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2080224862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224862.